Abstract
The background and aim of the study is to evaluate insulin sensitivity in hyperprolactinemic subjects via euglycemic hyperinsulinemic clamp technique. Sixteen hyperprolactinemic subjects and 12 healthy subjects were included in the study. HOMA-B and HOMA-IR values of groups were calculated. Euglycemic hyperinsulinemic clamp technique was performed in both groups, and the M value of the groups was defined. Mann–Whitney U and chi-square tests were used in statistical analysis. Basal insulin level of hyperprolactinemic patients were higher than the control group (6.85 ± 4.68; 3.66 ± 0.88 μU/ml respectively; P < 0.05). Mean HOMA-IR and HOMA-B values of patients were higher than control group (1.49 ± 1.30; 0.78 ± 0.27 respectively; P = 0.02 and 136.28 ± 72.53; 64.77 ± 23.31, respectively, P < 0.001). M values of the patients were statistically lower than the control group (5.64 ± 2.36; 7.05 ± 1.62 kg/mg/min respectively; P < 0.05). (1) Hyperprolactinemic patients were more insulin resistant than control subjects. (2) Insulin resistance in hyperprolactinemic patients is not associated with obesity or anthropometric parameters such as fat content, waist circumference and BMI.
Similar content being viewed by others
References
Baptista T et al (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305–1311. doi:10.1016/j.pnpbp.2004.08.001
Knudtzon J, Johansen PW, Haug E, Gautvik K (1986) Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-celltumor-bearing rats, and the influence of bromocriptine treatment. Life Sci 39:617–621. doi:10.1016/0024-3205(86)90042-1
Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol 264:E986–E992
Moore BJ, Gerardo-Gettens T, Horwitz BA, Stern JS (1986) Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 17:563–569. doi:10.1016/0361-9230(86)90226-1
Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén JM, Silvera R, Angeles F, Mendoza MT, Hernández L (2000) Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 33:81–88. doi:10.1055/s-2000-8451
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84. doi:10.1530/eje.0.1470077
Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547–553. doi:10.1046/j.1365-2265.1998.00403.x
Brandebourg T, Hugo E, Ben-Jonathan N (2007) Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9(4):464–476. doi:10.1111/j.1463-1326.2006.00671.x
Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574
Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246
Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142
Bahceci M, Tuzcu A, Bahceci S, Tuzcu S (2003) Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 26(7):655–659
Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26(4):341–346
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502
De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp tecnique: a method for quantifying insulin secretation and resistance. Am J Physiol 237:E214–E223
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419. doi:10.1007/BF00280883
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495. doi:10.2337/diacare.27.6.1487
Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390
Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726
Reis FM, Reis AM, Coimbra CC (1997) Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 153(3):423–428. doi:10.1677/joe.0.1530423
Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370
Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683–1707
Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834
Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396
Kok P, Roelfsema F, Frölich M, Meinders E, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445–4449
Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258
Asai-Sato M, Okamoto M, Endo M et al (2006) Hypoadiponectinemmia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 53:555–562
Nilsson L, Binart N, Bohlooly YM et al (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120–1126
Fuglsang J, Skjærbæk C, Frystyk J, Flyvbjerg A, Ovesen P (2006) A longitudinal study of serum adiponectin during normal pregnancy. BJOG 113(1):110–113. doi:10.1111/j.1471-0528.2005.00792.x
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuzcu, A., Yalaki, S., Arikan, S. et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 12, 330–334 (2009). https://doi.org/10.1007/s11102-009-0183-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-009-0183-1